Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial.
Altug
A
Kesikli
Saadettin
S
Kilickap
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D018719:Erb-b2 Receptor Tyrosine Kinases